polyglycolic acid

Summary

Summary: A biocompatible polymer used as a surgical suture material.

Top Publications

  1. ncbi Biodegradable nanoparticles for drug and gene delivery to cells and tissue
    Jayanth Panyam
    Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA
    Adv Drug Deliv Rev 55:329-47. 2003
  2. ncbi Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration
    Yin Meng Tsai
    Institute of Traditional Medicine, National Yang Ming University, Taipei, Taiwan
    Int J Pharm 416:331-8. 2011
  3. ncbi The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices
    R A Jain
    NanoSystems, a Division of Elan Pharmaceutical Technologies, King of Prussia, PA 19406, USA
    Biomaterials 21:2475-90. 2000
  4. pmc Current advances in research and clinical applications of PLGA-based nanotechnology
    Jian ming Lu
    Michael E DeBakey Department of Surgery, Division of Vascular Surgery and Endovascular Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Expert Rev Mol Diagn 9:325-41. 2009
  5. doi PLGA-based nanoparticles: an overview of biomedical applications
    Fabienne Danhier
    Universite Catholique de Louvain, Louvain Drug Research Institute, Pharmaceutics and Drug Delivery, Avenue Mounier, B1 73 12, 1200 Brussels, Belgium
    J Control Release 161:505-22. 2012
  6. ncbi Characterization of nanoparticle uptake by endothelial cells
    Jasmine Davda
    Department of Pharmaceutical Sciences, College of Pharmacy, 986025 Nebraska Medical Center, Omaha, NE 68198 6025, USA
    Int J Pharm 233:51-9. 2002
  7. ncbi Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake
    Sanjeeb K Sahoo
    Department of Pharmaceutical Sciences, University of Nebraska Medical Center 986025, Omaha, NE 68198 6025, USA
    J Control Release 82:105-14. 2002
  8. doi PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
    Sarbari Acharya
    Institute of Life Sciences, Nalco Square, Bhubaneswar, India
    Adv Drug Deliv Rev 63:170-83. 2011
  9. doi Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel
    Fabienne Danhier
    Universite Catholique de Louvain, Unite de Pharmacie Galenique, Avenue Mounier 73 20, 1200 Brussels, Belgium
    J Control Release 140:166-73. 2009
  10. doi Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation
    Fabienne Danhier
    Universite Catholique de Louvain, Unite de Pharmacie Galenique, Avenue Mounier, 73 20, 1200 Brussels, Belgium
    J Control Release 133:11-7. 2009

Detail Information

Publications357 found, 100 shown here

  1. ncbi Biodegradable nanoparticles for drug and gene delivery to cells and tissue
    Jayanth Panyam
    Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA
    Adv Drug Deliv Rev 55:329-47. 2003
    ..Based on the above mechanism, various potential applications of nanoparticles for delivery of therapeutic agents to the cells and tissue are discussed...
  2. ncbi Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration
    Yin Meng Tsai
    Institute of Traditional Medicine, National Yang Ming University, Taipei, Taiwan
    Int J Pharm 416:331-8. 2011
    ..These findings provide further understanding for the possible therapeutic effects of curcumin and C-NPs in further pre-clinical and clinical research...
  3. ncbi The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices
    R A Jain
    NanoSystems, a Division of Elan Pharmaceutical Technologies, King of Prussia, PA 19406, USA
    Biomaterials 21:2475-90. 2000
    ..Also, certain issues about other related biodegradable polyesters are discussed...
  4. pmc Current advances in research and clinical applications of PLGA-based nanotechnology
    Jian ming Lu
    Michael E DeBakey Department of Surgery, Division of Vascular Surgery and Endovascular Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Expert Rev Mol Diagn 9:325-41. 2009
    ....
  5. doi PLGA-based nanoparticles: an overview of biomedical applications
    Fabienne Danhier
    Universite Catholique de Louvain, Louvain Drug Research Institute, Pharmaceutics and Drug Delivery, Avenue Mounier, B1 73 12, 1200 Brussels, Belgium
    J Control Release 161:505-22. 2012
    ..This review focuses on the understanding of specific characteristics exploited by PLGA-based nanoparticles to target a specific organ or tissue or specific cells...
  6. ncbi Characterization of nanoparticle uptake by endothelial cells
    Jasmine Davda
    Department of Pharmaceutical Sciences, College of Pharmacy, 986025 Nebraska Medical Center, Omaha, NE 68198 6025, USA
    Int J Pharm 233:51-9. 2002
    ..Nanoparticles localized in the endothelium could provide prolonged drug effects because of their sustained release characterics, and also could protect the encapsulated agent from enzymatic degradation...
  7. ncbi Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake
    Sanjeeb K Sahoo
    Department of Pharmaceutical Sciences, University of Nebraska Medical Center 986025, Omaha, NE 68198 6025, USA
    J Control Release 82:105-14. 2002
    ..In conclusion, the residual PVA associated with nanoparticles is an important formulation parameter that can be used to modulate the pharmaceutical properties of PLGA nanoparticles...
  8. doi PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
    Sarbari Acharya
    Institute of Life Sciences, Nalco Square, Bhubaneswar, India
    Adv Drug Deliv Rev 63:170-83. 2011
    ..Ongoing research about drug-loaded nanoparticles and their delivery by the EPR effect to the tumour tissues has been elucidated in this review with clarity...
  9. doi Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel
    Fabienne Danhier
    Universite Catholique de Louvain, Unite de Pharmacie Galenique, Avenue Mounier 73 20, 1200 Brussels, Belgium
    J Control Release 140:166-73. 2009
    ..Hence, the targeting of anti-cancer drug to tumor endothelium by RGD-labeled NP is a promising approach...
  10. doi Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation
    Fabienne Danhier
    Universite Catholique de Louvain, Unite de Pharmacie Galenique, Avenue Mounier, 73 20, 1200 Brussels, Belgium
    J Control Release 133:11-7. 2009
    ..Therefore, PTX-loaded nanoparticles may be considered as an effective anticancer drug delivery system for cancer chemotherapy...
  11. pmc Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo
    Preetha Anand
    Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 143, Houston, TX 77030, USA
    Biochem Pharmacol 79:330-8. 2010
    ..Overall we demonstrate that curcumin-loaded PLGA nanoparticles formulation has enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo over curcumin...
  12. ncbi PLA/PLGA nanoparticles for sustained release of docetaxel
    T Musumeci
    Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Catania, Viale A Doria 6, I 95125 Catania, Italy
    Int J Pharm 325:172-9. 2006
    ..Kinetic experiments demonstrated that the release process of DTX form nanospheres is affected by the molecular weight of the employed polymers...
  13. ncbi Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells
    Murali Mohan Yallapu
    Cancer Biology Research Center, Sanford Research USD, Sioux Falls, SD 57105, USA
    J Colloid Interface Sci 351:19-29. 2010
    ....
  14. ncbi Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery
    Jayanth Panyam
    Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA
    FASEB J 16:1217-26. 2002
    ..S. Food and Drug Administration. Hence PLGA is well suited for sustained intracellular delivery of macromolecules...
  15. ncbi Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody
    Petra Kocbek
    University of Ljubljana, Faculty of Pharmacy, Askerceva 7, Ljubljana, Slovenia
    J Control Release 120:18-26. 2007
    ..Furthermore, the results show the effectiveness of the new carrier system for targeted delivery of small or large active substances into cells or tissues of interest...
  16. ncbi Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles
    Jayanth Panyam
    Department of Pharmaceutical Sciences, 986025 University of Nebraska Medical Center, Omaha, NE 68198 6025, USA
    J Control Release 92:173-87. 2003
    ..1 microm) as compared to the larger-size microparticles could explain some of the observed degradation results with different size particles...
  17. ncbi Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs
    Khin Yin Win
    Department of Chemical and Biomolecular Engineering, Faculty of Engineering, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260, Singapore
    Biomaterials 26:2713-22. 2005
    ..It is highly feasible for nanoparticles of biodegradable polymers to be applied to promote oral chemotherapy...
  18. ncbi Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine A-induced nephrotoxicity in rats
    K Sonaje
    Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research NIPER, SAS Nagar, Mohali, Punjab, 160062, India
    Pharm Res 24:899-908. 2007
    ..Ellagic acid (EA), a dietary antioxidant associated with poor biopharmaceutical properties, was encapsulated into poly(lactide-co-glycolide) (PLGA) and polycaprolactone (PCL) nanoparticles to improve oral bioavailability...
  19. pmc Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome
    Fiona A Sharp
    Adjuvant Research Group, School of Biochemistry and Immunology, Trinity College, Dublin 2, Ireland
    Proc Natl Acad Sci U S A 106:870-5. 2009
    ..Our data demonstrate that uptake of microparticulate adjuvants by DCs activates the NALP3 inflammasome, and this contributes to their enhancing effects on innate and antigen-specific cellular immunity...
  20. ncbi Effect of acidic pH on PLGA microsphere degradation and release
    Banu S Zolnik
    Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, United States
    J Control Release 122:338-44. 2007
    ..4. This is the first time that morphological changes during PLGA microsphere degradation have been compared for low and neutral pH and the data shows a change in the mechanism of degradation at the low pH...
  21. doi Preparation and characterization of a polymeric (PLGA) nanoparticulate drug delivery system with simultaneous incorporation of chemotherapeutic and thermo-optical agents
    Romila Manchanda
    Department of Biomedical Engineering, Florida International University, 10555 West Flagler Street, Miami, FL 33174, USA
    Colloids Surf B Biointerfaces 75:260-7. 2010
    ..022+/-0.001%, w/w, for DOX (n=3). The release pattern was biphasic. ICG and DOX loaded-nanoparticle preparation was standardized based on the following parameters: PLGA concentration, PVA concentration and initial drug content...
  22. ncbi Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy
    S Hariharan
    Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research NIPER, S A S Nagar, 160062, Punjab, India
    Pharm Res 23:184-95. 2006
    ..Histopathological examination and blood counts indicated the absence of inflammatory response. These data suggest that DMAB stabilized PLGA nanoparticles have great potential as carriers for oral delivery of estradiol...
  23. ncbi Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells
    Jayanth Panyam
    Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska 68198 6025, USA
    Pharm Res 20:212-20. 2003
    ..The purpose of this work was to characterize the process of endocytosis, exocytosis, and intracellular retention of poly (D,L-lactide-co-glycolide) nanoparticles in vitro using human arterial vascular smooth muscle cells (VSMCs)...
  24. pmc Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers
    Frank Gu
    Department of Chemical Engineering, Harvard MIT Center of Cancer Nanotechnology Excellence, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 105:2586-91. 2008
    ..This approach may contribute to further development of targeted NPs as highly selective and effective therapeutic modalities...
  25. ncbi Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives
    Raghavendra C Mundargi
    Industrial Biotechnology Group, Reliance Life Sciences Pvt Ltd, Dhirubhai Ambani Life Sciences Centre, Thane Belapur Road, Rabale, Navi Mumbai 400 701, India
    J Control Release 125:193-209. 2008
    ..The present review attempts to address some important data on nano/microparticle-based delivery systems of PLGA and PLGA-derived polymers with reference to macromolecular drugs...
  26. ncbi In vitro degradation of three-dimensional porous poly(D,L-lactide-co-glycolide) scaffolds for tissue engineering
    Linbo Wu
    Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science, Fudan University, No 220, Handan Road, Shanghai 200433, China
    Biomaterials 25:5821-30. 2004
    ....
  27. ncbi PLGA nanoparticles in drug delivery: the state of the art
    Indu Bala
    Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research NIPER, Punjab, India
    Crit Rev Ther Drug Carrier Syst 21:387-422. 2004
    ..Careful design of these delivery systems with respect to target and route of administration may solve some of the problems faced by new classes of active molecules...
  28. doi Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy
    Sarbari Acharya
    Institute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar, Orissa, India
    Biomaterials 30:5737-50. 2009
    ..Thus it was concluded that EGFR-Rapa-NPs provide an efficient and targeted delivery of anticancer drugs, presenting a promising active targeting carrier for tumor selective therapeutic treatment in near future...
  29. pmc The uptake and intracellular fate of PLGA nanoparticles in epithelial cells
    Malgorzata S Cartiera
    Department of Biomedical Engineering, Yale University, 55 Prospect Street, MEC 414, New Haven, CT 06520 8260, USA
    Biomaterials 30:2790-8. 2009
    ..We present a model for the intracellular fate of particles that is consistent with our experimental data...
  30. pmc Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy
    Stacey L Demento
    Department of Biomedical Engineering, Yale University, New Haven, CT 06511, USA
    Vaccine 27:3013-21. 2009
    ..The design of such an antigen delivery mechanism with the ability to stimulate two potent innate immune pathways represents a potent new approach to simultaneous antigen and adjuvant delivery...
  31. doi The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity
    Fei Yan
    The Shenzhen Key Laboratory of Gene and Antibody Therapy, Center for Biotech and Bio Medicine and Division of Life Sciences, Graduate School at Shenzhen, Tsinghua University, Shenzhen, People s Republic of China
    Nanomedicine 6:170-8. 2010
    ....
  32. ncbi Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin
    Yashu Yin
    Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning, 110016, China
    J Control Release 116:337-45. 2006
    ..These results confirmed that the conjugation of WGA onto PLGA nanoparticles effectively improved the intestinal absorption of TP5 due to specific bioadhesion on GI cell membrane...
  33. pmc Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines
    Anil Mahapatro
    Bioengineering Program and Department of Industrial and Manufacturing Engineering, Wichita State University, 1845 Fairmount Street, Wichita, KS 67260, USA
    J Nanobiotechnology 9:55. 2011
    ....
  34. pmc Polymeric nanoparticles for siRNA delivery and gene silencing
    Yogesh Patil
    Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA
    Int J Pharm 367:195-203. 2009
    ..Serum stability and lack of cytotoxicity further add to the potential of PLGA-PEI nanoparticles in gene silencing-based therapeutic applications...
  35. ncbi Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses
    M E Christine Lutsiak
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada T6G 2N8
    J Pharm Pharmacol 58:739-47. 2006
    ..The ability of PLGA nanoparticles to alter the type of immune response elicited by a peptide, even in the context of an ongoing immune response, makes PLGA nanoparticles a strong candidate for the formulation of therapeutic vaccines...
  36. pmc Decreased lung carcinoma cell density on select polymer nanometer surface features for lung replacement therapies
    Lijuan Zhang
    Department of Chemistry, Brown University, Providence, RI 02912, USA
    Int J Nanomedicine 5:269-75. 2010
    ..In this manner, PLGA with specific nanometer surface features may inhibit lung cancer cell density which may provide an important biomaterial for the treatment of lung cancer (from drug delivery to regenerative medicine)...
  37. ncbi Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells
    Kohei Tahara
    Laboratory of Pharmaceutical Engineering, School of Pharmaceutical Science, Aichi Gakuin University, 1 100, Kusumoto, Chikusa, Nagoya, Aichi 464 8650, Japan
    Int J Pharm 382:198-204. 2009
    ..CS-PLGA NSs were taken up by A549 cells in an energy-dependent manner, suggesting a clathrin-mediated endocytic process. CS-PLGA NS demonstrated low cytotoxicity, similar to non-PLGA NS...
  38. ncbi Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition
    Guixia Ling
    School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China
    J Control Release 148:241-8. 2010
    ..The new DPNs might provide an effective strategy for oral delivery of VCR with improved encapsulation efficiency and oral bioavailability...
  39. doi Interaction of biodegradable nanoparticles with intestinal cells: the effect of surface hydrophilicity
    Marie Gaumet
    Department of Pharmaceutics and Biopharmaceutics, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 30, quai E Ansermet, CH 1211 Geneva 4, Switzerland
    Int J Pharm 390:45-52. 2010
    ..The location of particles <300 nm appeared to be intracellular and some particles colocalized with the nucleus...
  40. ncbi Micro and nano-scale in vitro 3D culture system for cardiac stem cells
    Hossein Hosseinkhani
    International Research Institute for Integrated Medical Sciences IREIIMS, Tokyo Women s Medical University, Tokyo 162 8666, Japan
    J Biomed Mater Res A 94:1-8. 2010
    ..The use of micro- and nano-scale materials in the fabrication of composites together with a 3D culture system is a very promising way to promote the culture of stem cells. (c) 2009 Wiley Periodicals, Inc. J Biomed Mater Res, 2010...
  41. ncbi Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery
    Carrie S W Chong
    Faculty of Pharmacy and Pharmaceutical Sciences, Dentistry Pharmacy Building, University of Alberta, 3118 Edmonton, Alberta, Canada T6G 2N8
    J Control Release 102:85-99. 2005
    ..These findings suggest that appropriate design of the vaccine formulation and careful planning of the immunization schedule are important in the successful development of effective HBV therapeutic vaccines...
  42. pmc Design of curcumin loaded cellulose nanoparticles for prostate cancer
    Murali Mohan Yallapu
    Cancer Biology Research Center, Sanford Research University of South Dakota, Sioux Falls, SD 57104 0589, USA
    Curr Drug Metab 13:120-8. 2012
    ..Our study shows, for the first time, the feasibility of cellulose-CUR formulation and its potential use in prostate cancer therapy...
  43. doi Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats
    D R Kalaria
    Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research NIPER, S A S Nagar, 160 062, Punjab, India
    Pharm Res 26:492-501. 2009
    ..Doxorubicin, a potent anticancer drug associated with cardiotoxicity and low oral bioavailability, was loaded into nanoparticles with a view to improve its performance...
  44. ncbi Quantitative assessment of scaffold and growth factor-mediated repair of critically sized bone defects
    Megan E Oest
    Orthopaedic Research Laboratory, Woodruff School of Mechanical Engineering, Georgia Institute of Technology, IBB Room 2311, 315 Ferst Drive NW, Atlanta, Georgia 30332, USA
    J Orthop Res 25:941-50. 2007
    ..However, functional integration of the constructs appeared limited by continued presence of slow-degrading scaffolds and suboptimal dose or delivery of osteoinductive signals...
  45. ncbi Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution
    Yashu Yin
    Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning, 110016, China
    J Control Release 123:27-38. 2007
    ..These results further revealed the promising potential of lectin-conjugated nanoparticles on the improvement of intestinal bioadhesion and absorption for oral drug delivery...
  46. ncbi Evaluation of tissue-engineered vascular autografts
    Goki Matsumura
    Cardiovascular Surgery, Heart Institute of Japan, Tokyo Women s Medical University, Tokyo, Japan
    Tissue Eng 12:3075-83. 2006
    ..These results indicate that TEVAs are a biocompatible material with functional endothelial cells and biomechanical properties and do not have unwanted side effects...
  47. doi Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy
    Ranjita Misra
    Institute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar, Orissa, India
    Eur J Pharm Sci 39:152-63. 2010
    ..In conclusion, these results suggested that NLS conjugated doxorubicin loaded NPs could be potentially useful as novel drug delivery system for breast cancer therapy...
  48. ncbi Preparation of nanoparticles composed of poly(gamma-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells
    Hsiang Fa Liang
    Department of Chemical Engineering, National Tsing Hua University, Hsinchu, Taiwan, ROC
    J Control Release 105:213-25. 2005
    ..The aforementioned results indicated that the galactosylated nanoparticles prepared in the study had a specific interaction with HepG2 cells via ligand-receptor recognition...
  49. ncbi Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles
    Jayanth Panyam
    Department of Pharmaceutical Sciences, University of Nebraska Medical Center, 986025, Omaha, Nebraska 68198, USA
    J Pharm Sci 93:1804-14. 2004
    ..In conclusion, the solid-state drug-polymer solubility affects the nanoparticle characteristics, and thus could be used as an important preformulation parameter...
  50. ncbi Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity
    Samar Hamdy
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G 2N8, Canada
    Vaccine 26:5046-57. 2008
    ..These results support the potential use of PLGA nanoparticles as competent carriers for future cancer vaccine formulations...
  51. ncbi Formation of nanoparticles of a hydrophilic drug using supercritical carbon dioxide and microencapsulation for sustained release
    Amol J Thote
    Department of Chemical Engineering, Auburn University, Auburn, Alabama 36849 5127, USA
    Nanomedicine 1:85-90. 2005
    ....
  52. ncbi Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123
    G Tosi
    Department of Pharmaceutical Sciences, University of Modena and Reggio Emilia, Modena, Italy
    J Control Release 122:1-9. 2007
    ..The ability to enter the CNS appears to be linked to the sequence of the peptidic moiety present on their surface...
  53. ncbi Preparation and properties of poly(lactide-co-glycolide) (PLGA)/ nano-hydroxyapatite (NHA) scaffolds by thermally induced phase separation and rabbit MSCs culture on scaffolds
    Y X Huang
    Institute of Nano and Bio Polymeric Materials, Tongji University, Shanghai 200092, PR China
    J Biomater Appl 22:409-32. 2008
    ..NHA. The results suggest that the newly developed PLGA/NHA composite scaffolds may serve as an excellent 3D substrate for cell attachment and migration in bone tissue engineering...
  54. ncbi PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination
    Marie Garinot
    Universite Catholique de Louvain, Unite de Pharmacie Galenique, Brussels, Belgium
    J Control Release 120:195-204. 2007
    ..Finally, ovalbumin-loaded nanoparticles were orally administrated to mice and induced an IgG response, attesting antigen ability to elicit an immune response after oral delivery...
  55. ncbi Controlled release of sirolimus from a multilayered PLGA stent matrix
    Xintong Wang
    School of Materials Science and Engineering, Nanyang Technological University, Singapore, Singapore
    Biomaterials 27:5588-95. 2006
    ..The release of sirolimus can, on the other hand, be retarded by using a coating of a biodegradable polyester with a lauryl ester end group. Therefore, multilayered systems offer many options for controlling sirolimus release over months...
  56. ncbi Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms
    M L Houchin
    Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas, USA
    J Pharm Sci 97:2395-404. 2008
    ..This review summarizes the peptide/protein chemical degradation reactions that have been reported in PLGA systems and their mechanisms. Reported methods for stabilizing peptides and proteins in PLGA devices are also discussed...
  57. ncbi Porous poly(alpha-hydroxyacid)/Bioglass composite scaffolds for bone tissue engineering. I: Preparation and in vitro characterisation
    V Maquet
    Centre for Education and Research on Macromolecules, University of Liege, Belgium
    Biomaterials 25:4185-94. 2004
    ..Formation of hydroxyapatite on the surface of composites, as an indication of their bioactivity, was recorded by EDXA, X-ray diffractometry and confirmed by Raman spectroscopy...
  58. ncbi Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate
    Farnaz Esmaeili
    Novel Drug Delivery Systems Laboratory, Faculty of Pharmacy, Medical Sciences, University of Tehran, Tehran, Iran
    J Drug Target 16:415-23. 2008
    ..These results suggested that FOL-targeted DTX NPs could be a potentially useful delivery system for FOL-receptor-positive cancer cells...
  59. ncbi Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions
    Hiromitsu Yamamoto
    Gifu Pharmaceutical University, 5 6 1, Mitahora higashi Gifu 502 8585, Japan
    J Control Release 102:373-81. 2005
    ..4000)>FD-21 (Mw. 21,000)>FD70 (Mw. 70,000), which corresponded to the molecular weights ([Mw.] given in parentheses). The absorption-enhancing effect may have been caused by opening the intercellular tight junctions...
  60. doi Stabilizer-free poly(lactide-co-glycolide) nanoparticles for multimodal biomedical probes
    Fong Yu Cheng
    Department of Chemistry, National Cheng Kung University, Tainan 701, Taiwan, Republic of China
    Biomaterials 29:2104-12. 2008
    ..The iron oxide nanoparticles-conjugated PLGA nanoparticle showed high efficiency of relaxivities r2 and could be used as the powerful magnetic resonance imaging (MRI) agents...
  61. ncbi Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor
    Eun Seong Lee
    Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, 421 Wakara Way, Suite 315, Salt Lake City, Utah 84108, USA
    J Control Release 103:405-18. 2005
    ..The results demonstrate that PHSM/f is a viable means for treating drug resistant tumors...
  62. ncbi Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides
    Noha Nafee
    Biopharmaceutics and Pharmaceutical Technology, Saarland University, Saarbrucken, Germany
    Nanomedicine 3:173-83. 2007
    ..The study proved the efficacy of chitosan-coated PLGA nanoparticles as a flexible and efficient delivery system for antisense oligonucleotides to lung cancer cells...
  63. ncbi Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses
    Manish Diwan
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada
    J Drug Target 11:495-507. 2003
    ..0005). These results indicate that PLGA nanoparticles mimicking certain features of pathogens are efficient delivery systems for targeting vaccine antigens to DCs and activation of potent T cell responses...
  64. ncbi Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy
    Anindita Mukerjee
    Department of Molecular Biology, Institute for Cancer Research, Graduate School of Biomedical Sciences, University of North Texas, Health Science Center, Fort Worth, TX, 76107, USA
    Anticancer Res 29:3867-75. 2009
    ..Our present work investigated the efficiency of encapsulation of curcumin in poly (lactic-coglycolic acid) (PLGA) nanospheres using solid/oil/water emulsion solvent evaporation method...
  65. ncbi Endothelial and vascular smooth muscle cell function on poly(lactic-co-glycolic acid) with nano-structured surface features
    Derick C Miller
    Department of Biomedical Engineering, Purdue University, West Lafayette, IN 47907 1296, USA
    Biomaterials 25:53-61. 2004
    ....
  66. doi Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells
    Ranjita Misra
    Institute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar, Orissa, India
    Mol Pharm 8:852-66. 2011
    ..Overall, this combinational strategy has significant promise in the clinical management of intractable diseases, especially leukemia...
  67. doi Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile
    Noha Nafee
    Biopharmaceutics and Pharmaceutical Technology, Saarland University, Saarbrucken, Germany
    Int J Pharm 381:130-9. 2009
    ..In conclusion, there is an undeniable impact of cell type, medium, presence/absence of serum on the colloidal state of the particles that consequently influence their interaction with the cells...
  68. ncbi Critical determinants in PLGA/PLA nanoparticle-mediated gene expression
    Swayam Prabha
    Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA
    Pharm Res 21:354-64. 2004
    ..It was hypothesized that different formulation parameters could affect the nanoparticle characteristics and hence its gene transfection...
  69. pmc Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents
    R Dinarvand
    Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
    Int J Nanomedicine 6:877-95. 2011
    ....
  70. ncbi PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution
    Farnaz Esmaeili
    Novel Drug Delivery Systems Laboratory, Department of Pharmaceutics, Faculty of Pharmacy, Medical Sciences University of Tehran, P O Box 14155 6451, Tehran, Iran
    Int J Pharm 349:249-55. 2008
    ....
  71. doi Development of protein delivery microsphere system by a novel S/O/O/W multi-emulsion
    Weien Yuan
    Shanghai Jiaotong University, School of Pharmacy, 800 Dongchuan Road, Shanghai 200240, People s Republic of China
    Eur J Pharm Sci 36:212-8. 2009
    ..The dextran glassy particles can stabilize proteins in the PLGA matrix, which is the major advantage of this novel protein sustained-release system over preparation for the PLGA microspheres using W/O/W double-emulsion method...
  72. pmc Biodegradable nanoparticles for cytosolic delivery of therapeutics
    Jaspreet K Vasir
    Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Adv Drug Deliv Rev 59:718-28. 2007
    ....
  73. doi Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance
    Yogesh Patil
    Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA
    J Control Release 136:21-9. 2009
    ..Taken together, these results suggest that the use of targeted, dual agent nanoparticles delivering a combination of P-gp modulator and anticancer drug is a very promising approach to overcome tumor drug resistance...
  74. ncbi A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS
    L Mu
    Division of Bioengineering, The National University of Singapore, 9 Engineering Drive 1, 117576, Singapore, Singapore
    J Control Release 86:33-48. 2003
    ..Nanoparticles of nanometer size with narrow distribution can be obtained. A drug encapsulation efficiency as high as 100% can be achieved and the release kinetics can be controlled...
  75. doi Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles
    Christian Wischke
    Department of Pharmaceutical Sciences, University of Michigan, 428 Church Street, Ann Arbor, MI 48109 1065, USA
    Int J Pharm 364:298-327. 2008
    ..Overall, against the backdrop of an increasing number of new, poorly orally available drug entities entering development, microparticle delivery systems may be a viable strategy to rescue an otherwise undeliverable substance...
  76. ncbi Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro
    M A Tracy
    Alkermes Inc, Cambridge, MA 02139, USA
    Biomaterials 20:1057-62. 1999
    ..Finally, zinc carbonate was found to retard the degradation of some PLGs. These degradation studies have proved valuable in the design of sustained release microsphere products...
  77. ncbi Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo
    G Mittal
    Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, S A S Nagar, Punjab, India
    J Control Release 119:77-85. 2007
    ..Together, these results indicate that nanoparticulate formulations are ideal carriers for oral administration of estradiol having great potential to address the dose related issues of estradiol...
  78. ncbi Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content
    Avinash Budhian
    Department of Chemical and Biomolecular Engineering, University of Pennsylvania, 3231 Walnut St, Philadelphia, PA 19104 6272, United States
    Int J Pharm 336:367-75. 2007
    ..When optimized, the drug-loaded PLGA/PLA nanoparticles contain as much as 2.5% haloperidol...
  79. pmc Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB
    Guobao Wei
    Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109 2209, USA
    J Control Release 112:103-10. 2006
    ..The successful generation of 3-D nano-fibrous scaffold incorporating controlled-release factors indicates significant potential for more complex tissue regeneration...
  80. ncbi Synthesis and characterization of PLGA nanoparticles
    Carlos E Astete
    Department of Biological and Agricultural Engineering, Louisiana State University Agricultural Center, Baton Rouge 70803, USA
    J Biomater Sci Polym Ed 17:247-89. 2006
    ....
  81. ncbi Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity
    Cristina Fonseca
    Center for Neuroscience and Cell Biology of Coimbra, University of Coimbra, 3000, Coimbra, Portugal
    J Control Release 83:273-286. 2002
    ..Our results demonstrate that incorporation of Ptx in nanoparticles strongly enhances the cytotoxic effect of the drug as compared to Taxol, this effect being more relevant for prolonged incubation times...
  82. pmc PEGylated PLGA nanoparticles for the improved delivery of doxorubicin
    Jason Park
    Department of Biomedical Engineering, Yale University, New Haven, Connecticut, USA
    Nanomedicine 5:410-8. 2009
    ....
  83. pmc Reconstitutable charged polymeric (PLGA)(2)-b-PEI micelles for gene therapeutics delivery
    Deepa Mishra
    Department of Bioengineering, The University of Utah, 20 S 2030 E, RM 108, Salt Lake City, UT 84112, USA
    Biomaterials 32:3845-54. 2011
    ..These results indicate that this PLGA-b-bPEI polymeric micelle-based system is well suited as a reconstitutable gene delivery system, and has high potential for use as a delivery system for gene therapy applications...
  84. ncbi Stabilization and encapsulation of recombinant human erythropoietin into PLGA microspheres using human serum albumin as a stabilizer
    Jintian He
    Hebei Normal University, Hebei Province, People s Republic of China he
    Int J Pharm 416:69-76. 2011
    ..The results suggested that the integrity of rhEPO was successfully protected during the encapsulation process and the release period from polymeric matrices...
  85. doi Resorbable distraction of the mandible: technical evolution and clinical experience
    Fernando D Burstein
    Emory University Plastic Surgery Division, Center for Craniofacial Disorders, Children s Healthcare of Atlanta, Atlanta, Georgia, USA
    J Craniofac Surg 19:637-43. 2008
    ....
  86. pmc Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine
    James J Moon
    Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
    PLoS ONE 7:e31472. 2012
    ..vivax sporozoites. These results demonstrate that these VMP001-NPs are promising vaccines candidates that may elicit protective immunity against P. vivax sporozoites...
  87. ncbi Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide
    H B Ravivarapu
    Atrix Laboratories, Incorporated, 2579 Midpoint Drive, Fort Collins, CO 80525, USA
    Int J Pharm 194:181-91. 2000
    ..However, employing lower molecular weight polymer decreased the duration of efficacy of the formulation...
  88. doi Synthesis of lidocaine-loaded PLGA microparticles by flow focusing. Effects on drug loading and release properties
    M A Holgado
    Departamento de Farmacia y Tecnologia Farmaceutica, Facultad de Farmacia, Universidad de Sevilla, C Profesor García González 2, Seville, Spain
    Int J Pharm 358:27-35. 2008
    ..The FF technology allowed higher drug incorporations and slower release kinetics. The release studies showed a biphasic profile probably due to diffusion-cum-degradation mediated processes...
  89. ncbi Engineering of an elastic large muscular vessel wall with pulsatile stimulation in bioreactor
    Zhi C Xu
    Department of Plastic and Reconstructive Surgery, Shanghai 9th People s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Tissue Engineering, Shanghai, China
    Biomaterials 29:1464-72. 2008
    ..In the current study, an elastic large vessel wall (6mm in diameter) was engineered by loading a polyglycolic acid (PGA) unwoven fiber scaffold seeded with smooth muscle cells (SMCs) on a vessel reactor designed with ..
  90. ncbi Celecoxib-loaded poly(D,L-lactide-co-glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure
    Paul A McCarron
    School of Pharmacy, Queens University Belfast, Medical Biology Centre, Belfast, UK
    J Microencapsul 23:480-98. 2006
    ....
  91. ncbi Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density
    V C Mosqueira
    UMR CNRS 8612, , , , France
    Pharm Res 18:1411-9. 2001
    ..CONCLUSIONS: Covalently attached PEG on the surface of NCs substantially can reduce their clearance from the blood compartment and alter their biodistribution...
  92. ncbi [New surgical technique of pulmonary segmentectomy by ultrasonic scalpel and absorbable sealing materials]
    Y Matsumura
    Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
    Kyobu Geka 57:31-7. 2004
    ..Among 3 materials examined, best result was obtained with polyglycolic acid felt (PGAF:Neoveil). PGAF is a very soft and thin (0...
  93. doi Degradable polyester scaffolds with controlled surface chemistry combining minimal protein adsorption with specific bioactivation
    Dirk Grafahrend
    DWI e V and Institute of Technical and Macromolecular Chemistry, RWTH Aachen University, Pauwelsstr 8, D 52056 Aachen, Germany
    Nat Mater 10:67-73. 2011
    ..This approach permits synthetic materials to directly control cell behaviour, for example, resembling the binding of cells to fibronectin immobilized on collagen fibres in the extracellular matrix of connective tissue...
  94. ncbi PLG microsphere size controls drug release rate through several competing factors
    Cory Berkland
    Department of Chemical and Biomolecular Engineering, University of Illinois, Urbana, Illinois 61801, USA
    Pharm Res 20:1055-62. 2003
    ..We have fabricated uniform rhodamine- and piroxicam-containing microspheres, 10 to 100 microm in diameter, to better understand how microsphere size controls drug release...
  95. doi PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms
    Xiaoxia Xie
    Jiangsu Key Laboratory for Supramolecular Medicinal Materials and Applications, College of Life Sciences, Nanjing Normal University, Nanjing 210046, China
    J Agric Food Chem 59:9280-9. 2011
    ..Thus, encapsulating hydrophobic drugs on PLGA polymer is a promising method for sustained and controlled drug delivery with improved bioavailability of Biopharmaceutics Classification System (BCS) class IV, such as CUR...
  96. ncbi Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to caco-2 monolayers mimics particle uptake
    Peter Pietzonka
    Institute of Pharmaceutical Sciences, ETH Zurich
    Pharm Res 19:595-601. 2002
    ..Special emphasis was placed on the localization and the quantification of the uptake of fluorescently labeled polystyrene and poly(lactic-co-glycolic acid) (PLGA) nanoparticles...
  97. ncbi Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles
    K Avgoustakis
    Pharmaceutical Technology Laboratory, Department of Pharmacy, University of Patras, Rion 26500, Patras, Greece
    Int J Pharm 259:115-27. 2003
    ..This may be associated with the effects of the mPEG/PLGA ratio on the density of PEG on the surface of the nanoparticles and on the size of the nanoparticles...
  98. pmc Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides
    Jingwei Li
    Department of Pharmaceutics, School of Pharmacy, Fudan University, 826 Zhangheng Rd, Shanghai 201203, People s Republic of China
    Biomaterials 32:4943-50. 2011
    ..In conclusion, the Pep TGN is a motif never been reported before and Pep TGN modified nanoparticles showed great potential in targeted drug delivery across the blood brain barrier...
  99. ncbi Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches
    R Jain
    Department of Applied Pharmaceutical Sciences, The University of Rhode Island, Kingston 02881, USA
    Drug Dev Ind Pharm 24:703-27. 1998
    ..This review presents different preparation techniques of various drug-loaded PLGA devices, with special emphasis on preparing microparticles. Certain issues about other related biodegradable polyesters are discussed...
  100. pmc Advanced drug delivery systems of curcumin for cancer chemoprevention
    Shyam S Bansal
    Department of Pharmacology and Toxicology, University of Louisville Health Science Center, Louisville, Kentucky, USA
    Cancer Prev Res (Phila) 4:1158-71. 2011
    ....
  101. ncbi Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles
    A M Carcaboso
    Pharmacy and Pharmaceutical Technology Laboratory, Universidad del Pais Vasco UPV EHU, Paseo de la Universidad 7, 01006 Vitoria Gasteiz, Spain
    Vaccine 22:1423-32. 2004
    ..Since both types of response have been associated to protective immunity in malaria, we postulate that this new approach supposes an advantage over the traditional adjuvants and routes...

Research Grants68

  1. NARCOTICS, NALTREXONE AND MICROSOMAL ENZYMES
    ALBERT LANGLEY; Fiscal Year: 1980
    ..administered via subcutaneous implantation of naltrexone (2 mg)-containing beads consisting of a polylactic/polyglycolic acid copolymer (dynatech R/D Comp.). LAAM will be administered p.o...
  2. Engineered Cartilage Storage and Transport Solution
    Kelvin Brockbank; Fiscal Year: 2005
    ..TECCS will be manufactured using polyglycolic acid felt and human chondrocytes...
  3. A COMPARISON OF IN VIVO AND VITRO TISSUE ENGINEERING
    Bradley Kropp; Fiscal Year: 2003
    ..cell cultures from the host's native bladder and has shown promise for use with membranes fabricated from polyglycolic acid polymers (PAP)...
  4. A COMPARISON OF IN VIVO AND VITRO TISSUE ENGINEERING
    Bradley Kropp; Fiscal Year: 2002
    ..cell cultures from the host's native bladder and has shown promise for use with membranes fabricated from polyglycolic acid polymers (PAP)...
  5. A COMPARISON OF IN VIVO AND VITRO TISSUE ENGINEERING
    Bradley Kropp; Fiscal Year: 2004
    ..cell cultures from the host's native bladder and has shown promise for use with membranes fabricated from polyglycolic acid polymers (PAP)...
  6. A COMPARISON OF IN VIVO AND VITRO TISSUE ENGINEERING
    Bradley Kropp; Fiscal Year: 2000
    ..cell cultures from the host's native bladder and has shown promise for use with membranes fabricated from polyglycolic acid polymers (PAP)...
  7. A COMPARISON OF IN VIVO AND VITRO TISSUE ENGINEERING
    Bradley Kropp; Fiscal Year: 2001
    ..cell cultures from the host's native bladder and has shown promise for use with membranes fabricated from polyglycolic acid polymers (PAP)...
  8. MYOCARDIAL CONTROLLED RELEASE IMPLANTS FOR ARRHYTHMIAS
    Robert Levy; Fiscal Year: 1999
    ..Plasmid DNA delivery will be achieved using sustained release nanoparticles formulated from polylactic-polyglycolic acid (PLGA), with co-incorporated poly-L- lysine(PLL) to enhance DNA delivery...
  9. MYOCARDIAL CONTROLLED RELEASE IMPLANTS FOR ARRHYTHMIAS
    Robert Levy; Fiscal Year: 2000
    ..Plasmid DNA delivery will be achieved using sustained release nanoparticles formulated from polylactic-polyglycolic acid (PLGA), with co-incorporated poly-L- lysine(PLL) to enhance DNA delivery...
  10. CELL-POLYMER IMPLANT USING A RODENT BETA-CELL LINE
    Shelley Weinstock; Fiscal Year: 1993
    ..HIT-or RIN-cells will be seeded on available biodegradable, biocompatible polyglycolic acid or co-polymer of polylactic and polyglycolic acids...
  11. VITRIFICATION FOR TISSUE ENGINEERED BLOOD VESSELS
    Ying Song; Fiscal Year: 2004
    ..ice-free cryopreservation, known as vitrification, can have a salutary effects on the cryopreservation of polyglycolic acid - derived engineered vessels containing smooth muscle cells which otherwise sustain significant injury from ..
  12. VITRIFICATION FOR TISSUE ENGINEERED BLOOD VESSELS
    Ying Song; Fiscal Year: 2005
    ..ice-free cryopreservation, known as vitrification, can have a salutary effects on the cryopreservation of polyglycolic acid - derived engineered vessels containing smooth muscle cells which otherwise sustain significant injury from ..
  13. TISSUE ENGINEERING OF PULMONARY VALVES AND PULMONARY ART
    John Mayer; Fiscal Year: 2002
    ..The TE structures created using polyglycolic acid polymer have poor surgical handling characteristics...
  14. TISSUE ENGINEERING OF PULMONARY VALVES AND PULMONARY ART
    John Mayer; Fiscal Year: 2000
    ..The TE structures created using polyglycolic acid polymer have poor surgical handling characteristics...
  15. TISSUE ENGINEERING OF PULMONARY VALVES AND PULMONARY ART
    John Mayer; Fiscal Year: 2001
    ..The TE structures created using polyglycolic acid polymer have poor surgical handling characteristics...
  16. TISSUE ENGINEERING OF PULMONARY VALVES AND PULMONARY ART
    John Mayer; Fiscal Year: 2000
    ..The TE structures created using polyglycolic acid polymer have poor surgical handling characteristics...
  17. TISSUE ENGINEERING OF PULMONARY VALVES AND PULMONARY ART
    John Mayer; Fiscal Year: 1999
    ..The TE structures created using polyglycolic acid polymer have poor surgical handling characteristics...
  18. Functionally Graded Scaffolds for Tissue Engineering
    Suman Das; Fiscal Year: 2003
    ..will be fabricated using a selective laser sintering machine with powder materials including polylactic acid-polyglycolic acid copolymers (PLGA), and PLGA-Hydroxyapatite (HA) composites with different volume fractions of HA in the PLGA ..
  19. Functionally Graded Scaffolds for Tissue Engineering
    Suman Das; Fiscal Year: 2004
    ..will be fabricated using a selective laser sintering machine with powder materials including polylactic acid-polyglycolic acid copolymers (PLGA), and PLGA-Hydroxyapatite (HA) composites with different volume fractions of HA in the PLGA ..
  20. SITE-SPECIFIC GENE THERAPY FOR MYOCARDIAL ANGIOGENESIS
    Weiliam Chen; Fiscal Year: 2001
    ..the applicant proposes to: encapsulate DNA in small nanometer diameter particles with a poly-lactic-polyglycolic acid co-polymer, assess the in vitro delivery mechanism of nanoparticles using beta -galactosidase as a model ..
  21. BIODEGRADABLE RELEASE NANOPARTICLES FOR RESTENOSIS
    Vinod Labhasetwar; Fiscal Year: 1999
    ..Polylactic/polyglycolic acid copolymers and polycaprolactones will be used to form 100nm diameter of nanoparticles...
  22. BIODEGRADABLE RELEASE NANOPARTICLES FOR RESTENOSIS
    Vinod Labhasetwar; Fiscal Year: 2000
    ..Polylactic/polyglycolic acid copolymers and polycaprolactones will be used to form 100nm diameter of nanoparticles...
  23. SITE-SPECIFIC GENE THERAPY FOR MYOCARDIAL ANGIOGENESIS
    Weiliam Chen; Fiscal Year: 2000
    ..the applicant proposes to: encapsulate DNA in small nanometer diameter particles with a poly-lactic-polyglycolic acid co-polymer, assess the in vitro delivery mechanism of nanoparticles using beta -galactosidase as a model ..
  24. SITE-SPECIFIC GENE THERAPY FOR MYOCARDIAL ANGIOGENESIS
    Weiliam Chen; Fiscal Year: 1999
    ..the applicant proposes to: encapsulate DNA in small nanometer diameter particles with a poly-lactic-polyglycolic acid co-polymer, assess the in vitro delivery mechanism of nanoparticles using beta -galactosidase as a model ..
  25. Nanoparticle targeting of ICAM-1 as a potential treatment for Rheumatoid Arthriti
    Cory Berkland; Fiscal Year: 2007
    ..Here, we propose a potentially more selective approach for treating RA by attempting to localize drugs to molecular markers of inflammation (ICAM-1) as an alternative to systemic immunosuppression. ..
  26. Formulation & Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
    Susan Mallery; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  27. Orchestrating Bone Regeneration on Multiple Scales
    Peter Ma; Fiscal Year: 2007
    ..SA 3. Confirm that the multi-scaled and factor-releasing scaffolds (selected from Aims 1&2) afford a superior environment for vascularized bone regeneration in a rat critical defect model. ..
  28. Orchestrating Bone Regeneration on Multiple Scales
    Peter Ma; Fiscal Year: 2008
    ..SA 3. Confirm that the multi-scaled and factor-releasing scaffolds (selected from Aims 1&2) afford a superior environment for vascularized bone regeneration in a rat critical defect model. ..
  29. Evaluation of bioadhesive berry gels for oral cancer chemoprevention
    Susan Mallery; Fiscal Year: 2008
    ..These studies will test the effects of bioadhesive gels, which contain naturally occurring cancer fighting compounds, to determine the gels' chemopreventive (cancer fighting) abilities on explants of human oral mouth tissues. ..
  30. Role of Oxidants & Angiogenesis in Kaposi's Sarcoma
    Susan Mallery; Fiscal Year: 2007
    ..Elucidation of these interactions will not only clarify KS pathogenic mechanisms, but will also identify sites for KS therapeutic intervention. ..
  31. Nano Fibers for ADME/Toxicology
    Peter Ma; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  32. Nano Fibers for ADME/Toxicology
    Peter Ma; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  33. Periodontal Engineering Using Biomimetic Nano Scaffolds
    Peter Ma; Fiscal Year: 2009
    ..This project should significantly advance our capacity to design a modality for restoring periodontal wounds resulted from periodontitis, leading to advanced new regenerative therapies. ..
  34. Periodontal Engineering Using Biomimetic Nano Scaffolds
    Peter X Ma; Fiscal Year: 2010
    ..This project should significantly advance our capacity to design a modality for restoring periodontal wounds resulted from periodontitis, leading to advanced new regenerative therapies. ..
  35. Chemoprevention of Head & Neck Cancer Using Controlled Release Polymers
    Susan R Mallery; Fiscal Year: 2010
    ....
  36. Periodontal Engineering Using Biomimetic Nano Scaffolds
    Peter Ma; Fiscal Year: 2009
    ..This project should significantly advance our capacity to design a modality for restoring periodontal wounds resulted from periodontitis, leading to advanced new regenerative therapies. ..
  37. Chemoprevention of Head & Neck Cancer Using Controlled Release Polymers
    Susan Mallery; Fiscal Year: 2009
    ....
  38. Periodontal Engineering Using Biomimetic Nano Scaffolds
    Peter Ma; Fiscal Year: 2008
    ..This project should significantly advance our capacity to design a modality for restoring periodontal wounds resulted from periodontitis, leading to advanced new regenerative therapies. ..
  39. Orchestrating Bone Regeneration on Multiple Scales
    Peter X Ma; Fiscal Year: 2010
    ..SA 3. Confirm that the multi-scaled and factor-releasing scaffolds (selected from Aims 1&2) afford a superior environment for vascularized bone regeneration in a rat critical defect model. ..
  40. Orchestrating Bone Regeneration on Multiple Scales
    Peter Ma; Fiscal Year: 2009
    ..SA 3. Confirm that the multi-scaled and factor-releasing scaffolds (selected from Aims 1&2) afford a superior environment for vascularized bone regeneration in a rat critical defect model. ..
  41. Nanoparticle targeting of ICAM-1 as a potential treatment for Rheumatoid Arthriti
    Cory Berkland; Fiscal Year: 2008
    ..Here, we propose a potentially more selective approach for treating RA by attempting to localize drugs to molecular markers of inflammation (ICAM-1) as an alternative to systemic immunosuppression. ..
  42. Chemoprevention of Head & Neck Cancer Using Controlled Release Polymers
    Susan R Mallery; Fiscal Year: 2011
    ....
  43. Periodontal Engineering Using Biomimetic Nano Scaffolds
    Peter Ma; Fiscal Year: 2006
    ..abstract_text> ..
  44. Role of Oxidants & Angiogenesis in Kaposi's Sarcoma
    Susan Mallery; Fiscal Year: 2006
    ..Elucidation of these interactions will not only clarify KS pathogenic mechanisms, but will also identify sites for KS therapeutic intervention. ..
  45. Periodontal Engineering Using Biomimetic Nano Scaffolds
    Peter Ma; Fiscal Year: 2003
    ..abstract_text> ..
  46. Biomimetic Nano Scaffolds
    Peter Ma; Fiscal Year: 2004
    ..This knowledge will enable us to develop a predictable biomimetic scaffold for in vivo application and will be the basis for our planned R01 investigation. ..
  47. Role of Oxidants & Angiogenesis in Kaposi's Sarcoma
    Susan Mallery; Fiscal Year: 2004
    ..Elucidation of these interactions will not only clarify KS pathogenic mechanisms, but will also identify sites for KS therapeutic intervention. ..
  48. Periodontal Engineering Using Biomimetic Nano Scaffolds
    Peter Ma; Fiscal Year: 2004
    ..abstract_text> ..
  49. Role of Oxidants & Angiogenesis in Kaposi's Sarcoma
    Susan Mallery; Fiscal Year: 2003
    ..Elucidation of these interactions will not only clarify KS pathogenic mechanisms, but will also identify sites for KS therapeutic intervention. ..
  50. Role of Oxidants & Angiogenesis in Kaposi's Sarcoma
    Susan Mallery; Fiscal Year: 2005
    ..Elucidation of these interactions will not only clarify KS pathogenic mechanisms, but will also identify sites for KS therapeutic intervention. ..
  51. Periodontal Engineering Using Biomimetic Nano Scaffolds
    Peter Ma; Fiscal Year: 2005
    ..abstract_text> ..
  52. Chemoprevention of Oral Dysplasia by Black Raspberries
    Susan Mallery; Fiscal Year: 2005
    ..This experimental design (comparison of pretreatment and post-treatments tissues) permits each patient to serve as their own internal control. ..
  53. Gene Delivery Stents
    Robert Levy; Fiscal Year: 2005
    ..The therapeutic gene will be Fas-Ligand, a pro-apoptotic protein with established efficacy for restenosis. The chief therapeutic endpoint will be extent of inhibition of neointimal formation. ..
  54. BIOENGINEERING OF BLADDER TISSUES
    Anthony Atala; Fiscal Year: 1999
    ..In this aim we will attempt to determine the phenotypic and functional characteristics, over time, of the bioengineered bladder tissues, as compared to controls. ..
  55. Insulin Producing Cells from Amniotic Stem Cells for Diabetes Therapy
    Anthony Atala; Fiscal Year: 2009
    ..Successful development of an abundant source of transplantable insulin producing cells potentially would have a profound impact on the treatment of a major public health problem. ..
  56. Polyurethane Calcification:Mechanism and Inhibition
    Robert Levy; Fiscal Year: 2001
    ..abstract_text> ..
  57. Protein Stability in Polymer Delivery Systems
    STEVEN SCHWENDEMAN; Fiscal Year: 2009
    ..model proteins and peptides in PLGA delivery systems, 3) application of the stabilization methodology to the delivery of angiogenic proteins, and 4) in vivo assessment of the controlled release of biologically active angiogenic proteins ..
  58. Protein Stability in Polymer Delivery Systems
    STEVEN SCHWENDEMAN; Fiscal Year: 2001
    ....
  59. Polyurethane Calcification:Mechanism and Inhibition
    Robert Levy; Fiscal Year: 2002
    ..abstract_text> ..
  60. Protein Stability in Polymer Delivery Systems
    STEVEN SCHWENDEMAN; Fiscal Year: 2008
    ..proteins and peptides in PLGA delivery systems, 3) application of the stabilization methodology to the delivery of angiogenic proteins, and 4) in vivo assessment of the controlled release of biologically active angiogenic proteins ..
  61. Mechanisms of In-Vivo Remodeling in Tissue Engineered Heart Valves
    Michael Sacks; Fiscal Year: 2007
    ..Relevance to public health includes the develop of valved pulmonary conduits for the pediatric population that can grow with the patient, minimizing the need for continued re-operations to bring the patient to adulthood. ..
  62. Recognition of Mtb-infected cells by CD8+ T lymphocytes
    David M Lewinsohn; Fiscal Year: 2010
    ..AIM 2: Establish whether or not the Mtb-phagosome is a competent antigen processing organelle AIM 3: Characterize Mtb-reactive alpha beta TCR expressing thymocytes ..
  63. MYOCARDIAL CONTROLLED RELEASE IMPLANTS FOR ARRHYTHMIAS
    Robert Levy; Fiscal Year: 2001
    ..Plasmid DNA delivery will be achieved using sustained release nanoparticles formulated from polylactic-polyglycolic acid (PLGA), with co-incorporated poly-L- lysine(PLL) to enhance DNA delivery...
  64. Pharmacology of Antiretroviral Nanoparticle Micelles
    Christopher Destache; Fiscal Year: 2008
    ..This nanoparticle delivery system could affect the future of HIV- 1 treatment. [unreadable] [unreadable] [unreadable] [unreadable]..